BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Fuji
UBS
US Department of Justice
Healthtrust
McKinsey
Accenture
Mallinckrodt
Cipla
Covington

Generated: January 19, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,415,363

« Back to Dashboard

Summary for Patent: 8,415,363
Title:Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide
Abstract: Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.
Inventor(s): Manley; Paul W (Arlesheim, CH), Shieh; Wen-Chung (Berkeley Heights, NJ), Sutton; Paul Allen (Parsippany, NJ), Karpinski; Piotr "Peter" H (Lincoln Park, NJ), Wu; Raeann R (Pine Brook, NJ), Monnier; Stephanie M (Raedersheim, FR), Brozio; Jorg (Basel, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:13/565,913
Patent Claims: 1. A crystalline form B of the hydrochloride salt of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide as a monohydrate, characterized by an x-ray powder diffraction pattern having at least one maxima selected from about 7.2.degree., 9.2.degree., 11.4.degree., 12.0.degree., 12.3.degree., 14.6.degree., 14.8.degree., 15.7.degree., 17.6.degree., 19.2.degree., 19.5,.degree. 20.5.degree., 22.0.degree., 23.4.degree., 23.9.degree., 25.0.degree., 25.5.degree., 25.9.degree., 27.0.degree. (2.theta. degrees) as shown in FIG. 8.

2. The crystalline form of claim 1, characterized by an x-ray powder diffraction pattern having maxima at about 7.2.degree., 9.2.degree., 11.4.degree., 12.0.degree., 12.3.degree., 14.6.degree., 14.8.degree., 15.7.degree., 17.6.degree., 19.2.degree., 19.5,.degree. 20.5.degree., 22.0.degree., 23.4.degree., 23.9.degree., 25.0.degree., 25.5.degree., 25.9.degree., 27.0.degree. (2.theta. degrees).

3. A pharmaceutical composition comprising: (a) a therapeutically effective amount of crystalline form B of the hydrochloride salt of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl -pyrimidin-2-ylamino)-benzamide as a monohydrate according to claim 1; and (b) at least one pharmaceutically acceptable carrier, diluent or excipient.

4. A method of treating chronic myelogenous leukemia comprising the step of administering to a subject in need thereof, a therapeutically effective amount of crystalline form B of the hydrochloride salt of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide as a monohydrate according to claim 1.

5. A crystalline form B' of the anhydrous hydrochloride salt of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide, characterized by an x-ray powder diffraction pattern having at least one maxima selected from about 7.2.degree., 9.2.degree., 11.5.degree., 12.0.degree., 13.9.degree., 14.3.degree., 15.4.degree., 17.6.degree., 18.6.degree., 20.3.degree., 21.7.degree., 22.5.degree., 23.2.degree., 24.7.degree., 24.9.degree., 25.2.degree., 26.0.degree., 26.6.degree., 27.5.degree., 28.2.degree., 29.2.degree. and 30.0.degree. (2.theta. degrees) as shown in FIG. 9.

6. The crystalline form of claim 5, characterized by an x-ray powder diffraction pattern having maxima at about 7.2.degree., 9.2.degree., 11.5.degree., 12.0.degree., 13.9.degree., 14.3.degree., 15.4.degree., 17.6.degree., 18.6.degree., 20.3.degree., 21.7.degree., 22.5.degree., 23.2.degree., 24.7.degree., 24.9.degree., 25.2.degree., 26.0.degree., 26.6.degree., 27.5.degree., 28.2.degree., 29.2.degree. and 30.0.degree. (2.theta. degrees).

7. A pharmaceutical composition comprising: (a) a therapeutically effective amount of crystalline form B' of the anhydrous hydrochloride salt of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-- 3-(4-pyridin-3-yl -pyrimidin-2-ylamino)-benzamide according to claim 5; and (b) at least one pharmaceutically acceptable carrier, diluent or excipient.

8. A method of treating chronic myelogenous leukemia comprising the step of administering to a subject in need thereof, a therapeutically effective amount of crystalline form B' of the anhydrous hydrochloride salt of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-- 3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide according to claim 5.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Federal Trade Commission
US Department of Justice
Novartis
Healthtrust
QuintilesIMS
US Army
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot